The demand for Lipid-Lowering Agents in D-A-CH has been steadily increasing over the years.
Customer preferences: In D-A-CH, customers are increasingly concerned about their health and well-being. This has led to a rise in demand for Lipid-Lowering Agents as they help in reducing cholesterol levels and preventing cardiovascular diseases. Customers are also becoming more conscious of the side effects of medication and are opting for products with natural ingredients.
Trends in the market: Germany is the largest market for Lipid-Lowering Agents in D-A-CH, followed by Switzerland and Austria. The market is dominated by statins, which account for the majority of sales. However, there has been a shift towards non-statin drugs such as PCSK9 inhibitors, ezetimibe, and omega-3 fatty acids. This is due to the increasing number of patients who are unable to tolerate statins or do not achieve their target cholesterol levels with statin therapy alone.
Local special circumstances: In Switzerland, the market for Lipid-Lowering Agents is heavily regulated, with the government setting a maximum price for drugs. This has led to lower prices for customers but has also resulted in limited access to newer and more expensive drugs. In Austria, the market is dominated by generic drugs, which are cheaper than branded drugs. However, this has also led to a lack of innovation in the market.
Underlying macroeconomic factors: The aging population in D-A-CH has contributed to the increasing demand for Lipid-Lowering Agents. As people age, their cholesterol levels tend to increase, leading to a higher risk of cardiovascular diseases. Additionally, the high prevalence of obesity and unhealthy lifestyles in the region has also contributed to the rise in demand for Lipid-Lowering Agents. The strong healthcare infrastructure and high disposable income in D-A-CH have also made it easier for customers to access and afford these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
